Insulin Receptor anticorps (PE)

N° du produit ABIN2662548

Détail du produit anti-Insulin Receptor anticorps (PE)

Antigène: Insulin Receptor (INSR)

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Insulin Receptor est conjugé à/à la PE

Application: Flow Cytometry (FACS), Cytometry by Time of Flight (CyTOF)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: B6-220

Isotype: IgG2b kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur Insulin Receptor

Antigène: Insulin Receptor (INSR)

Autre désignation: CD220 (INSR Produits)

Synonymes: anticorps CD220, anticorps HHF5, anticorps 4932439J01Rik, anticorps D630014A15Rik, anticorps IR, anticorps IR-A, anticorps IR-B, anticorps 18402, anticorps CG18402, anticorps DIHR, anticorps DILR, anticorps DIR, anticorps DIRH, anticorps DIRbeta, anticorps DInR, anticorps DInr, anticorps Dir-a, anticorps Dir-b, anticorps Dmel\\CG18402, anticorps INR, anticorps INS, anticorps Inr, anticorps Inr-alpha, anticorps Inr-beta, anticorps InsR, anticorps dINR, anticorps dIR, anticorps dIRH, anticorps dInR, anticorps dInr, anticorps dInsR, anticorps dinr, anticorps dir, anticorps er10, anticorps inr, anticorps insulin/insulin-like growth factor receptor, anticorps l(3)05545, anticorps l(3)93Dj, anticorps l(3)er10, anticorps lnR, anticorps ir-A, anticorps CTK-1, anticorps ir, anticorps INSR, anticorps NV14476, anticorps cd220, anticorps hhf5, anticorps insulin receptor, anticorps Insulin-like receptor, anticorps insulin receptor L homeolog, anticorps INSR, anticorps Insr, anticorps InR, anticorps LOC100122567, anticorps LOC100451802, anticorps insr.L

Sujet: CD220, also known as insulin receptor, is a type I transmembrane receptor tyrosine kinase composed of two extracellular α-subunits and two transmembrane β-subunits. Binding insulin, the insulin receptor forms a heterotetramer of two units to induce autophosphorylation and activation of the tyrosine kinase activity of the receptor. Activation of insulin receptor leads to subsequent downstream signaling in metabolic regulation, inducing glucose uptake, cell growth, differentiation, and apoptosis. Gene mutation in the insulin receptor or decreased insulin receptor signaling leads to insulin-resistant diabetes mellitus and noninsulin-dependent diabetes mellitus (diabetes mellitus type 2). Most normal cells constitutively express insulin receptors. In hematopoietic cells, insulin receptor is constitutively expressed on monocytes and selectively expressed on activated lymphocytes.

Pathways: Signalisation NF-kappaB, Signalisation RTK, AMPK Signaling, Carbohydrate Homeostasis, Regulation of Cell Size, Regulation of Carbohydrate Metabolic Process, Growth Factor Binding, Negative Regulation of Transporter Activity